CFD Research has secured a competitive $1.6 million Grant from the NIH National Center for Complementary and Integrative Health (NCCIH). This significant achievement will provide nondilutive funding to advance the innovative Kalm Patch into clinical trials for the treatment of eczema and psoriasis.
CFD Research is excited to announce the formation of Kalm Therapeutics (Kalm Tx) to bring a much-needed non-steroidal eczema treatment to patients with mild to moderate atopic dermatitis (~16M Americans).
CFD Research has been awarded a $1.5M Phase II Defense Health Agency (DHA) Small Business Innovative Research (SBIR) contract to develop extremophile-derived antivirals to protect soldiers and civilians from COVID-19. Selection was based on achievements during previous drug discovery projects and a novel strategy for targeting the SARS-CoV-2 virus which causes COVID-19.
At the HudsonAlpha Institute for Biotechnology, casual gatherings can lead to incredible research opportunities. Most recently at the Institute, a fortuitous encounter at a HudsonAlpha mixer led to a collaboration that will search for new ways to treat pancreatic cancer.